Associations between changes in dopamine and noradrenaline transporters and clinical symptoms in patients with ADHD taking methylphenidate

Associations between changes in dopamine and noradrenaline transporters and clinical symptoms in patients with ADHD taking methylphenidate - Associations between changes in dopamine and noradrenaline transporters and clinical symptoms in patients with ADHD taking methylphenidate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038895

Enrollment

Registered

2020-02-01

Start date

2020-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD

Interventions

healthy controls patients with ADHD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants who can understand the content of this study. Each patient must meet the diagnostic criterion. Only patients being prescribed methylphenidate for a clinical reason can be included.

Exclusion criteria

Exclusion criteria: Subjects with severe physical, or other psychiatric diseases Subjects with strong suicidal ideation Subjects during (probable) pregnancy or breast-feeding Subjects who were judged not suitable for other reasons

Design outcomes

Primary

Measure	Time frame
Associations between binding changes in dopamine and noradrenaline transporters and symptom changes by conducting two sets of PET scans (with and without taking methylphenidate)	—

Countries

Japan

Contacts

Public ContactKazuko Suzuki

National Institutes for Quantum and Radiological Science and Technology Clinical Research Section

suzuki.kazuko@qst.go.jp+81-43-206-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026